Medical - Care Facilities
Compare Stocks
2 / 10Stock Comparison
LFST vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
LFST vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Care Facilities | Biotechnology |
| Market Cap | $3.43B | $1712.35T |
| Revenue (TTM) | $1.49B | $0.00 |
| Net Income (TTM) | $23M | $-168M |
| Gross Margin | 21.7% | — |
| Operating Margin | 3.0% | — |
| Forward P/E | 121.1x | — |
| Total Debt | $194M | $22M |
| Cash & Equiv. | $249M | $194M |
LFST vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 21 | May 26 | Return |
|---|---|---|---|
| LifeStance Health G… (LFST) | 100 | 31.8 | -68.2% |
| DBV Technologies S.… (DBVT) | 100 | 36.6 | -63.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: LFST vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
LFST carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.20
- Rev growth 13.9%, EPS growth 113.3%, 3Y rev CAGR 18.3%
- -59.6% 10Y total return vs DBVT's -87.0%
DBVT is the clearest fit if your priority is momentum.
- +110.4% vs LFST's +60.6%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 13.9% revenue growth vs DBVT's -100.0% | |
| Quality / Margins | 1.6% margin vs DBVT's 0.3% | |
| Stability / Safety | Beta 1.20 vs DBVT's 1.26, lower leverage | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +110.4% vs LFST's +60.6% | |
| Efficiency (ROA) | 1.1% ROA vs DBVT's -89.0% |
LFST vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
Insufficient data to determine a leader in this category.
Income & Cash Flow (Last 12 Months)
LFST and DBVT operate at a comparable scale, with $1.5B and $0 in trailing revenue.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $1.5B | $0 |
| EBITDAEarnings before interest/tax | $100M | -$112M |
| Net IncomeAfter-tax profit | $23M | -$168M |
| Free Cash FlowCash after capex | $179M | -$151M |
| Gross MarginGross profit ÷ Revenue | +21.7% | — |
| Operating MarginEBIT ÷ Revenue | +3.0% | — |
| Net MarginNet income ÷ Revenue | +1.6% | — |
| FCF MarginFCF ÷ Revenue | +12.0% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +21.2% | — |
| EPS Growth (YoY)Latest quarter vs prior year | — | +91.5% |
Valuation Metrics
DBVT leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $3.4B | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $3.4B | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | 442.50x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | 121.07x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 41.98x | — |
| Price / SalesMarket cap ÷ Revenue | 2.41x | — |
| Price / BookPrice ÷ Book value/share | 2.28x | 0.66x |
| Price / FCFMarket cap ÷ FCF | 31.20x | — |
Profitability & Efficiency
LFST leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
LFST delivers a 1.6% return on equity — every $100 of shareholder capital generates $2 in annual profit, vs $-130 for DBVT. LFST carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to DBVT's 0.13x. On the Piotroski fundamental quality scale (0–9), LFST scores 7/9 vs DBVT's 4/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +1.6% | -130.2% |
| ROA (TTM)Return on assets | +1.1% | -89.0% |
| ROICReturn on invested capital | +1.2% | — |
| ROCEReturn on capital employed | +1.3% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 4 |
| Debt / EquityFinancial leverage | 0.13x | 0.13x |
| Net DebtTotal debt minus cash | -$55M | -$172M |
| Cash & Equiv.Liquid assets | $249M | $194M |
| Total DebtShort + long-term debt | $194M | $22M |
| Interest CoverageEBIT ÷ Interest expense | 3.30x | -189.82x |
Total Returns (Dividends Reinvested)
Evenly matched — LFST and DBVT each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LFST five years ago would be worth $4,041 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, DBVT leads with a +110.4% total return vs LFST's +60.6%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs LFST's 1.4% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +27.2% | +4.9% |
| 1-Year ReturnPast 12 months | +60.6% | +110.4% |
| 3-Year ReturnCumulative with dividends | +4.1% | +19.7% |
| 5-Year ReturnCumulative with dividends | -59.6% | -69.1% |
| 10-Year ReturnCumulative with dividends | -59.6% | -87.0% |
| CAGR (3Y)Annualised 3-year return | +1.4% | +6.2% |
Risk & Volatility
LFST leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
LFST is the less volatile stock with a 1.20 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LFST currently trades 99.6% from its 52-week high vs DBVT's 76.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.20x | 1.26x |
| 52-Week HighHighest price in past year | $8.89 | $26.18 |
| 52-Week LowLowest price in past year | $3.74 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +99.6% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 60.4 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 2.9M | 252K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates LFST as "Buy" and DBVT as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 5.1% for LFST (target: $9).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $9.30 | $46.33 |
| # AnalystsCovering analysts | 11 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
LFST leads in 2 of 6 categories (Profitability & Efficiency, Risk & Volatility). DBVT leads in 1 (Valuation Metrics). 1 tied.
LFST vs DBVT: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is LFST or DBVT a better buy right now?
LifeStance Health Group, Inc.
(LFST) offers the better valuation at 442. 5x trailing P/E (121. 1x forward), making it the more compelling value choice. Analysts rate LifeStance Health Group, Inc. (LFST) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — LFST or DBVT?
Over the past 5 years, LifeStance Health Group, Inc.
(LFST) delivered a total return of -59. 6%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: LFST returned -59. 6% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — LFST or DBVT?
By beta (market sensitivity over 5 years), LifeStance Health Group, Inc.
(LFST) is the lower-risk stock at 1. 20β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 5% more volatile than LFST relative to the S&P 500. On balance sheet safety, LifeStance Health Group, Inc. (LFST) carries a lower debt/equity ratio of 13% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.
04Which is growing faster — LFST or DBVT?
On earnings-per-share growth, the picture is similar: LifeStance Health Group, Inc.
grew EPS 113. 3% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — LFST or DBVT?
LifeStance Health Group, Inc.
(LFST) is the more profitable company, earning 0. 7% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 0. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LFST leads at 1. 8% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — LFST leads at 28. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is LFST or DBVT more undervalued right now?
Analyst consensus price targets imply the most upside for DBVT: 131.
8% to $46. 33.
07Which pays a better dividend — LFST or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is LFST or DBVT better for a retirement portfolio?
For long-horizon retirement investors, LifeStance Health Group, Inc.
(LFST) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 20)). Both have compounded well over 10 years (LFST: -59. 6%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between LFST and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.